drug discovery
About 300 million prescription records were used to train the AI to reveal drug safety issues and opportunities for repurposing medicines.
The new firm will offer partners an expanded range of methods and workflows for small-molecule and peptide drug discovery.
The company unveiled TxGemma, a collection of Gemma-based open models aimed at improving the efficiency of AI-powered drug discovery, during its recent Check Up event.
The company, in partnership with Microsoft, aims to develop cancer medicines, followed by treatments for autoimmune diseases and rare conditions.
The money will be used to develop new medications and biologicals.
Tx-LLM was fine-tuned from Google's Med-PaLM 2 and created to analyze a variety of chemical or biological entities to assist with the drug-discovery pipeline.
TenAces will develop an AI platform to help identify protein interactions that naturally occur in the body to assist with targeted protein degradation.
The companies will leverage Absci's AI-enabled Integrated Drug Creation platform and the pharma giant's oncology research and development expertise.
The company will use the funds to grow its drug-discovery pipeline and clinical AI stack.
Mati Gil, CEO of AION Labs, describes how its new startup OMEC.AI came to fruition and what it aims to accomplish for drug discovery and development.